XF platform to be tested against CF-related MRSA lung infection
Destiny Pharma is launching a research program to test a potential therapy derived from its XF drug platform for methicillin-resistant Staphylococcus aureus (MRSA) lung infections in people with cystic fibrosis (CF). The program will test the potency of an experimental treatment known as XF-73 in MRSA samples from CF…